7 assets in CBL-Related Disorder

Therapeutic assets addressing CBL-Related Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells CBL-Related Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit CBL-Related Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Busulfanum CBL-Related Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cyclophosphamide CBL-Related Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Fludarabine CBL-Related Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Melphalan CBL-Related Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rituximab CBL-Related Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)